Streetbeat News

PBLA

Panbela Therapeutics Inc.

http://www.sunbiopharma.com/

CEO

Michael Cullen

Open

0.32

Mkt cap

1.6M

Volume

6.3K

High

0.33

P/E Ratio

N/A

52-wk high

38.00

Low

0.32

Div yield

N/A

52-wk low

0.30

Several healthcare stocks experienced significant movement in Wednesday's pre-market session. Notable gainers included Cellectis, Monopar Therapeutics, ZyVersa Therapeutics, TG Therapeutics, Aldeyra Therapeutics, and Artelo Biosciences. On the other hand, Iridex, Tonix Pharmaceuticals, Kintara Therapeutics, G1 Therapeutics, Turnstone Biologics, and Panbela Therapeutics saw their stocks decline.

Portfolio Pulse from Benzinga Insights

November 01, 2023 | 1:06 pm

Panbela Therapeutics, Inc. (NASDAQ:PBLA) has announced the validation of its European patent for a novel process for the production of SBP-101 in the UK, Italy, Germany, France, and Spain. The patent, developed in collaboration with Syngene International Ltd., reduces the number of synthetic steps from seventeen to six. The patent is valid until 2039 and covers a shorter synthesis of SBP-101, which provides a scalable, efficient, and cost-effective manufacturing process.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:17 pm

In Wednesday's after-market session, several healthcare stocks saw significant movement. Gainers included Clene (CLNN), AcelRx Pharmaceuticals (ACRX), Assembly Biosciences (ASMB), GRI Bio (GRI), China SXT Pharmaceuticals (SXTC), and Biomerica (BMRA). Losers included Align Tech (ALGN), Simulations Plus (SLP), Alpha Tau Medical (DRTS), Reshape Lifesciences (RSLS), Forian (FORA), and Panbela Therapeutics (PBLA).

Portfolio Pulse from Benzinga Insights

October 25, 2023 | 9:31 pm

Panbela Therapeutics has announced that an abstract on SBP-101 and CPP-1X has been accepted for online publication on the ASH Meeting site.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 12:19 pm

On Tuesday, 132 companies hit new 52-week lows. Among them, Corning (NYSE:GLW) was the largest in terms of market cap, while Wheeler Real Estate IT (NASDAQ:WHLR) was the smallest. Fortress Biotech (NASDAQ:FBIO) saw the largest move with shares plummeting 1350.03%, while Insulet (NASDAQ:PODD) made the biggest bounce back, moving up 0.0% shortly after hitting a new 52-week low.

Portfolio Pulse from Benzinga Insights

October 10, 2023 | 5:09 pm

Panbela Therapeutics (NASDAQ:PBLA) has announced the issuance of a new patent in China for a novel process for the production of SBP-101, a lead investigational product. The patent, developed in collaboration with Syngene International Ltd., reduces the number of synthetic steps from seventeen to six, making the production more scalable, efficient, and cost-effective. The patent is valid until 2039 and is expected to improve the overall competitiveness of SBP-101 in the market.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 12:19 pm

Smith & Wesson Brands, Inc. (NASDAQ:SWBI) shares gained 11.5% in pre-market trading after the company reported better-than-expected financial results. Other pre-market gainers include Impel Pharmaceuticals Inc. (NASDAQ:IMPL), AGBA Group Holding Limited (NASDAQ:AGBA), BioNexus Gene Lab Corp. (NASDAQ:BGLC), and Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE). On the other hand, Grom Social Enterprises, Inc. (NASDAQ:GROM), Digital Media Solutions, Inc. (NYSE:DMS), Kaixin Auto Holdings (NASDAQ:KXIN), Rosecliff Acquisition Corp I (NASDAQ:RCLF), and Inpixon (NASDAQ:INPX) fell in pre-market trading.

Portfolio Pulse from Lisa Levin

September 08, 2023 | 12:28 pm

Panbela Therapeutics, Inc. (NASDAQ:PBLA) has announced the issuance of a new patent in Chile for its product Flynpovi, a fixed dose formulation of eflornithine and sulindac developed in collaboration with Sanofi. The patent, which is valid until 2036, has also been issued in the US, Australia, Mexico, and Taiwan. Flynpovi is Panbela's lead investigational product for the treatment of Familial Adenomatous Polyposis (FAP).

Portfolio Pulse from Happy Mohamed

September 05, 2023 | 12:16 pm

Panbela Therapeutics has announced the issuance of a new patent in Europe for claims of a novel process for the production of SBP-101. This development could potentially enhance the company's intellectual property portfolio and its competitive position in the market.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 12:16 pm

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Panbela Therapeutics (NASDAQ:PBLA) and maintained a $16 price target.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 4:56 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.